| Literature DB >> 34139875 |
Amir Khoshbin1, Graeme Hoit1, Lauren Leone Nowak2, Anser Daud1, Martine Steiner3, Peter Juni4, Bheeshma Ravi5, Amit Atrey1.
Abstract
AIMS: While preoperative bloodwork is routinely ordered, its value in determining which patients are at risk of postoperative readmission following total knee arthroplasty (TKA) and total hip arthroplasty (THA) is unclear. The objective of this study was to determine which routinely ordered preoperative blood markers have the strongest association with acute hospital readmission for patients undergoing elective TKA and THA.Entities:
Keywords: Arthroplasty; Preoperative bloodmarkers; Preoperative screening; Readmission; Total hip arthroplasty; Total knee arthroplasty
Year: 2021 PMID: 34139875 PMCID: PMC8244797 DOI: 10.1302/2633-1462.26.BJO-2021-0020
Source DB: PubMed Journal: Bone Jt Open ISSN: 2633-1462
Fig. 1Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)[30] diagram of cohort assembly for total knee arthroplasty (TKA) and total hip arthroplasty (THA) patients. NSQIP, National Quality Improvement Programme.
Summary of patients.
| Variable | TKA cohort | THA cohort |
|---|---|---|
| Mean age, yrs (SD) | 66.6 (9.6) | 64.7 (11.4) |
| Female sex, n (%) | 85,163 (61.7) | 42,637 (54.3) |
|
| ||
| White | 109,179 (79.1) | 64,370 (82.0) |
| Black | 10,939 (7.9) | 6,478 (8.3) |
| Other | 17,851 (12.9) | 7,684 (9.7) |
| Independent functional status | 136,484 (98.9) | 77,241 (98.4) |
| Mean BMI, kg/m2 (SD) | 33.2 (6.8) | 30.4 (6.3) |
| Smoker, n (%) | 11,766 (8.5) | 10,392 (13.2) |
| CHF, n (%) | 442 (0.3) | 259 (0.3) |
| COPD, n (%) | 5143 (3.7) | 3,181 (4.1) |
| Diabetes, n (%) | 25,660 (18.6) | 9,673 (12.3) |
| Dialysis, n (%) | 262 (0.2) | 157 (0.2) |
| Hypertension, n (%) | 91,673 (66.4) | 44,953 (57.2) |
| Steroid use, n (%) | 5,487 (4.0) | 3,152 (4.0) |
| Bleeding disorder, n (%) | 3,111 (2.3) | 1,620 (2.1) |
| Dyspnea, n (%) | 8,387 (6.1) | 3,730 (4.8) |
|
| ||
| I/II | 67,731 (49.1) | 44,494 (56.7) |
| III/IV | 70,238 (50.9) | 34,038 (43.3) |
|
| ||
| General | 70,317 (51.0) | 43,515 (55.4) |
| Neuraxial | 67,652 (49.0) | 35,017 (44.6) |
| Mean operation length, mins (SD) | 92.4 (33.6) | 92.5 (38.4) |
| Mean length of stay, days (SD) | 2.6 (2.4) | 2.2 (1.4) |
|
| ||
| Home | 106,562 (77.2) | 63,529 (80.9) |
| Other | 31,407 (22.8) | 15,003 (19.1) |
ASA, American Society of Anesthesiologists; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; SD, standard deviation; THA, total hip arthroplasty; TKA, total knee arthroplasty.
Preoperative laboratory results.
| Preoperative blood marker | TKA cohort | THA cohort |
|---|---|---|
|
| ||
| Mean albumin g/l (SD) | 41.1 (0.37) | 41.5 (0.39) |
| Low (0 to 34 g/l), n (%) | 5,253 (3.8) | 2,658 (3.4) |
| Normal (35+ g/l), n (%) | 132,716 (96.2) | 75,874 (96.6) |
|
| ||
| Mean HCT L/L (SD) | 41.0 (4.1) | 41.2 (4.2) |
| Low (Male < 45 L/L, Female < 37 L/L), n (%) | 43,239 (31.3) | 28,020 (35.7) |
| Normal, n (%) | 94,730 (68.7) | 50,512 (64.3) |
|
| ||
| Mean platelets 109/l (SD) | 245.0 (66.6) | 248.5 (67.7) |
| Low (0 to 139 × 109/l), n (%) | 4,248 (3.1) | 2,142 (2.7) |
| Normal (140+ × 109/l), n (%) | 133,721 (96.9) | 76,390 (97.3) |
|
| ||
| Mean WBC 109/l (SD) | 7.0 (2.1) | 7.0 (2.3) |
| Low/Normal (0 to 11 × 109/l), n (%) | 133,222 (96.6) | 75,592 (96.3) |
| High (12+ × 109/l), n (%) | 4,747 (3.4) | 2,940 (3.7) |
|
| ||
| Mean eGFR, ml/min/1.73 m2 (SD) | 82.2 (24.4) | 84.7 (25.4) |
| Severe (< 30 ml/min/1.73 m2), n (%) | 1,022 (0.7) | 574 (0.7) |
| Mild/Moderate (30 to 89 ml/min/1.73 m2), n (%) | 102,066 (66.7) | 49,073 (62.5) |
| Normal (≥ 90 ml/min/1.73 m2), n (%) | 44,881 (32.5) | 28,885 (36.8) |
|
| ||
| Mean sodium, mmol/l (SD) | 139.8 (2.8) | 139.7 (2.8) |
| Low (< 135 mmol/l), n (%) | 4,808 (3.5) | 3,173 (4.0) |
| Normal (135 to 147 mmol/l), n (%) | 132,889 (96.3) | 75,222 (95.8) |
| High (≥ 148 mmol/l), n (%) | 272 (0.2) | 137 (0.2) |
eGFR, estimate glomerular filtration rate; HCT, hematocrit; preop, preoperative; SD, standard deviation; THA, total hip arthroplasty; TKA, total knee arthroplasty; WBC, white blood cell count.
Univariable association of continuous blood marker results with acute readmission in development and validation.
| TKA | THA | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Development (2011 to 2016) | Validation (2017 to 2018) | Development (2011 to 2016) | Validation (2017 to 2018) | ||||
| Patients, n | 82,810 | 55,159 | 46,889 | 31,643 | ||||
| Readmissions, n (%) | 2,635 (3.2) | 1,748 (3.2) | 1,623 (3.5) | 1,102 (3.5) | ||||
|
|
|
|
|
|
|
|
| |
| Albumin | 0.69 (0.64 to 0.74) | < 0.0001 | 0.64 (0.59 to 0.70) | < 0.0001 | 0.64 (0.58 to 0.70) | < 0.0001 | 0.55 (0.49 to 0.61) | < 0.001 |
| HCT | 0.79 (0.73 to 0.85) | < 0.0001 | 0.70 (0.64 to 0.77) | < 0.0001 | 0.75 (0.69 to 0.83) | < 0.0001 | 0.56 (0.50 to 0.62) | < 0.0001 |
| Platelets | 0.84 (0.77 to 0.91) | < 0.0001 | 0.81 (0.73 to 0.89) | < 0.0001 | 0.98 (0.89 to 1.08) | 0.6835 | 0.98 (0.87 to 1.10) | 0.6927 |
| WBC | 1.20 (1.13 to 1.28) | < 0.0001 | 1.22 (1.12 to 1.32) | < 0.0001 | 1.19 (1.11 to 1.29) | < 0.0001 | 1.33 (1.21 to 1.46) | < 0.0001 |
| eGFR | 0.62 (0.56 to 0.67) | < 0.0001 | 0.60 (0.54 to 0.66) | < 0.0001 | 0.81 (0.72 to 0.90) | < 0.0001 | 0.65 (0.57 to 0.74) | < 0.0001 |
| Sodium | 0.86 (0.80 to 0.93) | < 0.0001 | 0.83 (0.76 to 0.91) | < 0.0001 | 0.91 (0.82 to 1.00) | 0.0502 | 0.84 (0.75 to 0.94) | 0.0032 |
Odds ratios are standardized to demonstrate odds adjustment per two standard deviation incremental increase in each variable, allowing for magnitude comparison between variables. Odds ratios are unadjusted. Variables are considered statistically significant if p < 0.0005 is maintained across both development and validation cohorts.
CI, confidence interval; eGFR, estimated glomerular filtration rate; HCT, haematocrit; OR, odds ratio; THA, total hip arthroplasty; TKA, total knee arthroplasty; WBC, white blood cell count.
Univariable association of blood marker results categorized by clinically relevant cutoffs and acute readmission.
| Preoperative blood marker | TKA | THA | ||||||
|---|---|---|---|---|---|---|---|---|
| Development (2011 to 2016) | Validation (2017 to 2018) | Development (2011 to 2016) | Validation (2017 to 2018) | |||||
| OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
|
| ||||||||
| Low (0 to 34) | 1.88 (1.60 to 2.20) | < 0.0001 | 2.43 (2.05 to 2.89) | < 0.0001 | 2.01 (1.63 to 2.48) | < 0.0001 | 2.59 (2.26 to 2.96) | < 0.0001 |
| Normal (35+) | Ref. | Ref. | Ref. | Ref. | ||||
|
| ||||||||
| Low (M: < 45, F: < 37) | 1.48 (1.37 to 1.61) | < 0.0001 | 1.57 (1.42 to 1.73) | < 0.0001 | 1.18 (1.07 to 1.31) | 0.0011 | 1.45 (1.28 to 1.60) | < 0.0001 |
| Normal | Ref. | Ref. | Ref. | Ref. | ||||
|
| ||||||||
| Low (0 to 139) | 1.59 (1.33 to 1.91) | < 0.0001 | 1.83 (1.47 to 2.28) | < 0.0001 | 1.73 (1.35 to 2.20) | < 0.0001 | 1.65 (1.23 to 2.22) | 0.0007 |
| Normal (140+) | Ref. | Ref. | Ref. | Ref. | ||||
|
| ||||||||
| Low/Normal (0 to 11) | Ref. | Ref. | Ref. | Ref. | ||||
| High (12+) | 1.37 (1.14 to 1.65) | < 0.0001 | 1.45 (1.16 to 1.82) | 0.0012 | 1.67 (1.35 to 2.07) | < 0.0001 | 1.67 (1.30 to 2.16) | < 0.0001 |
|
| ||||||||
| Severe (< 30) | 3.32 (2.50 to 4.42) | < 0.0001 | 3.99 (2.78 to 5.72) | < 0.0001 | 2.30 (1.50 to 3.51) | < 0.0001 | 3.99 (2.60 to 6.13) | < 0.0001 |
| Mild/Mod. (30 to 89) | 1.25 (1.15 to 1.37) | 1.34 (1.21 to 1.50) | 1.09 (0.98 to 1.21) | 1.34 (0.17 to 1.53) | ||||
| Normal (≥ 90) | Ref. | Ref. | Ref. | Ref. | ||||
|
| ||||||||
| Low (< 135) | 1.56 (1.32 to 1.85) | < 0.0001 | 1.39 (1.10 to 1.76) | 0.0199 | 1.35 (1.08 to 1.68) | < 0.0001 | 1.67 (1.26 to 2.15) | 0.0004 |
| Normal (135 to 147) | Ref. | Ref. | Ref. | Ref. | ||||
| High (≥ 148) | 1.14 (0.51 to 2.59) | 0.61 (0.15 to 2.48) | 3.94 (1.96 to 7.92) | 0.93 (0.23 to 3.81) | ||||
Odds ratios (OR) are unadjusted. Variables are considered statistically significant if p < 0.0005 is maintained across both development and validation cohorts.
CI, confidence interval; eGFR, estimated glomerular filtration rate; Mod, moderate; N/A, not applicable; Ref, reference category; THA, total hip arthroplasty; TKA, total knee arthroplasty; WBC, white blood cell count.
Multivariable regression of the association between continuous blood marker results and acute readmission.
| Variable | TKA | THA | ||||||
|---|---|---|---|---|---|---|---|---|
| Development (2011 to 2016) | Validation (2017 to 2018) | Development (2011 to 2016) | Validation (2017 to 2018) | |||||
| Patients, n | 82,810 | 55,159 | 46,889 | 31,643 | ||||
| Readmissions, n (%) | 2,635 (3.2) | 1,748 (3.2) | 1,623 (3.5) | 1,102 (3.5) | ||||
|
|
|
|
|
|
|
|
| |
| Albumin | 0.82 (0.76 to 0.88) | < 0.0001 | 0.80 (0.73 to 0.88) | < 0.0001 | 0.82 (0.74 to 0.91) | < 0.0001 | 0.78 (0.69 to 0.89) | < 0.0001 |
| HCT | 0.86 (0.80 to 0.94) | 0.0005 | 0.81 (0.73 to 0.89) | < 0.0001 | 0.89 (0.80 to 0.99) | 0.0258 | 0.70 (0.62 to 0.89) | < 0.0001 |
| Platelets | 0.93 (0.85 to 1.01) | 0.0688 | 0.89 (0.89 to 0.98) | 0.0242 | 1.00 (0.90 to 1.10) | 0.9404 | 0.98 (0.86 to 1.11) | 0.7156 |
| WBC | 1.13 (1.05 to 1.21) | 0.0008 | 1.14 (1.04 to 1.25) | 0.0054 | 1.09 (1.01 to 1.17) | 0.0281 | 1.18 (1.06 to 1.32) | 0.0027 |
| eGFR | 0.75 (0.69 to 0.83) | < 0.0001 | 0.78 (0.71 to 0.87) | < 0.0001 | 1.00 (0.90 to 1.11) | 0.9371 | 0.96 (0.84 to 1.09) | 0.4929 |
| Sodium | 0.90 (0.83 to 0.97) | 0.0057 | 0.88 (0.80 to 0.96) | 0.0063 | 0.98 (0.88 to 1.08) | 0.6214 | 0.93 (0.83 to 1.05) | 0.2568 |
Odds ratios are standardized to demonstrate odds adjustment per two standard deviation incremental increase in each variable, allowing for magnitude comparison between variables. Odds ratios are adjusted for the patient and treatment factors listed in Table I – adjusted odds ratios for these variables are presented in Supplementary Material 4. Variables are considered statistically significant if p < 0.0005 is maintained across both development and validation cohorts.
CI, confidence interval; eGFR, estimated glomerular filtration rate; HCT, haematocrit; OR, odds ratio; WBC, white blood cell count.
Multivariable regression of the association of blood marker results categorized by clinically relevant cutoffs and acute readmission.
| Preoperative blood marker | TKA | THA | ||||||
|---|---|---|---|---|---|---|---|---|
| Development (2011 to 2016) | Validation (2017 to 2018) | Development (2011 to 2016) | Validation (2017 to 2018) | |||||
| OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | OR (95% CI) | p-value | |
|
| ||||||||
| Low (0 to 34) | 1.40 (1.19 to 1.65) | < 0.001 | 1.77 (1.48 to 2.12) | < 0.001 | 1.39 (1.12 to 1.73) | 0.0029 | 1.53 (1.20 to 1.93) | < 0.001 |
| Normal (35+) | Ref. | Ref. | Ref. | Ref. | ||||
|
| ||||||||
| Low (M: < 45, F: < 37) | 1.17 (1.06 to 1.28) | 0.0016 | 1.25 (1.11 to 1.41) | < 0.001 | 1.04 (0.92 to 1.18) | 0.4910 | 1.39 (1.20 to 1.62) | < 0.001 |
| Normal | Ref. | Ref. | Ref. | Ref. | ||||
|
| ||||||||
| Low (0 to 139) | 1.14 (0.94 to 1.37) | 0.1787 | 1.31 (1.04 to 1.64) | 0.0227 | 1.35 (1.05 to 1.74) | 0.0199 | 1.19 (0.87 to 1.62) | 0.2780 |
| Normal (140+) | Ref. | Ref. | Ref. | Ref. | ||||
|
| ||||||||
| Low/Normal (0 to 11) | Ref. | Ref. | Ref. | Ref. | ||||
| High (12+) | 1.16 (0.96 to 1.40) | 0.1313 | 1.18 (0.93 to 1.48) | 0.1676 | 1.32 (1.06 to 1.64) | 0.0123 | 1.24 (0.95 to 1.61) | 0.1176 |
|
| ||||||||
| Severe (< 30) | 2.00 (1.45 to 2.76) | < 0.001 | 1.62 (1.04 to 2.50) | < 0.001 | 1.38 (0.86 to 2.21) | 0.5106 | 1.32 (0.75 to 2.30) | 0.1364 |
| Mild/Mod. (30 to 89) | 1.13 ( | 1.21 (1.08 to 1.36) | 0.94 (0.84 to 1.05) | 1.10 (0.96 to 1.27) | ||||
| Normal (≥ 90) | Ref. | Ref. | Ref. | Ref. | ||||
|
| ||||||||
| Low (< 135) | 1.39 (1.17 to 1.65) | < 0.001 | 1.17 (0.91 to 1.49) | 0.1642 | 1.14 (0.91 to 1.43) | 0.6907 | 1.29 (0.99 to 1.68) | 0.0506 |
| Normal (135 to 147) | Ref. | Ref. | Ref. | Ref. | ||||
| High (≥ 148) | 1.06 (0.46 to 2.40) | 0.56 (0.14 to 2.30) | 3.67 (1.80 to 7.49) | 0.75 (0.18 to 3.12) | ||||
Odds ratios are adjusted for previously listed covariates in Table I. Variables are considered statistically significant if p < 0.0005 is maintained across both development and validation cohorts.
CI, confidence interval; eGFR, estimated glomerular filtration rate; Mod, moderate; OR, odds ratio; Ref, reference category; THA, total hip arthroplasty; TKA, total knee arthroplasty; WBC, white blood cell count.